Scientific Advisory Board
quality and affordable protein therapeutics
Amgen、Genentech、Lilly、Applied Molecular Evolution (Eli Lilly)、Bristol-Myers Squibb、Bayer等国际顶级生物医药公司服务多年。他们对新型复杂生物药——包括单克隆抗体及融合蛋白等产品的开发及商品化整套流程具有广泛而丰富的实践及管理经验，无论是在抗体工程、细胞株开发、产程/分析方法开发，还是在GMP生产管理、质量监控、临床研究、全球药政事务等方面都有深厚造诣和产业界实务经验。
Dr. Scott Liu, the co-founder and Head of Strategic Advisory Committee at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to setting up Henlius in 2010, he has previously had postdoctoral training in Biology at Stanford University and has served several executive positions at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb Technical Operations, and the Director of QAL (QC) at Amgen Inc. Fremont (now Boehringer Ingelheim Fremont Inc.). Dr. Liu was the recipient of the Bristol-Myers Squibb “Technical Operations Presidential Award” in 2004. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China. He received his Ph.D. degree in Biology from the Purdue University.
Dr. Weidong Jiang, the Co-founder and Co-head of Innovative Advisory Committee at Shanghai Henlius Biotech Inc., graduated from Hangzhou University with a bachelor degree of biology, and Chinese Academy of Sciences with a master degree of cell biology. He later continued his Ph.D. study in Microbiology and Molecular Biology in the University of Giessen in Germany. After that, he did his post-doctoral research at University of California. Following his academic career, he developed his expertise in biopharmaceutical R&D and production, including drug discovery, antibody/protein engineering, production cell line development, process optimization, and regulatory filing, by serving as a senior scientist and/or director for companies such as Applied Molecular Evolution Inc. and Vasgene Therapeutics Inc.
Kun-Liang Guan, Chairman of Henlius Scientific Advisory Board, is a Distinguished Professor of Pharmacology at the University of California, San Diego. He obtained his BS (1982) at Hangzhou University, China and Ph.D. (1989) at Purdue University. From 1992-2007, Guan was a faculty at the University of Michigan. He received the MacArthur Fellowship, the American Society of Biochemistry and Molecular Biology Young Investigator Award, Distinguished Alumni Award from Purdue University, an AAAS Fellow, and is a highly cited researcher in Molecular Biology & Genetics (Thomson Reuters). Guan studies signaling mechanisms of cell growth and tumorigenesis, particular focusing on the mTOR and Hippo pathways.
Yiping Yang, member of Henlius Scientific Advisory Board, Director, Division of Hematology, Professor of Medicine, the Ohio State University. Dr. Yang received his M.D. from Zhejiang University, and Ph.D. from University of Michigan. He then completed his postdoctoral training and Internal Medicine residency at the University of Pennsylvania, and his Medical Oncology fellowship at Johns Hopkins University. He is an ABIM-certified physician with clinical interest in lymphoma and leukemia. He has been selected as America’s top oncologist since 2008. He has also served as Associate Editor for Journal of Clinical Investigation (JCI) and JCI Insight. Funded by grants from National Institute of Health and private foundations, his research focuses on cancer immunology and immunotherapy, as well as gene therapy and viral immunity. He has published more than 100 peer-reviewed papers in journals including Science, Nature Immunology, Nature Genetics, Nature Medicine, Immunity, JCI, PNAS, etc.
Weiping Zou, member of Henlius Scientific Advisory Board, is a faculty at the University of Michigan. His research interests are in tumor immunopathology and immunotherapy. Over the past few years, his research team has achieved important insights into cancer immunopathogenesis. His research efforts demonstrate that the tumor microenvironment is comprised of immune cells that have been reprogrammed by active tumor-mediated processes to defeat tumor immunity and promote tumor progression in a highly effective manner. These studies have helped define the nature of immune responses in the cancer microenvironment, form the concept of immunosuppressive networks in the cancer microenvironment and provide significant insights into designing current immune therapies including inhibitory B7 checkpoint blockade (PD-L1, B7-H1) to treat cancer patients. The Zou laboratory is one of the most cited research teams in the field of Cancer Immunology. Dr. Zou is/was an editorial board member for 9 scientific journals. He has delivered more than 200 invited lectures. He serves as a reviewer for more than 15 funding agencies including NIH and DOD, and for more than 50 scientific journals including New England Journal of Medicine, Cell, Science, and Nature journals. He is the AACR Cancer Immunology Chairperson-elect 2018-2019.
Zihai Li, member of Henlius Scientific Advisory Board, is Klotz Memorial Chair in Cancer Research, Professor and Founding Director of the Pelotonia Institute for Immuno-Oncology at The Ohio State University James Comprehensive Cancer Center. He received his Ph.D. in Microbiology & Immunology from Icahn School of Medicine at Mount Sinai, New York. He completed his internal medicine residency in the Montefiore-Einstein Medical Center and his medical oncology fellowship at the Fred Hutchinson Cancer Research Center. Prior to his current position, he was chair of the Department of Microbiology and Immunology and co-leader of the Cancer Immunology Program at the NCI-designated Hollings Cancer Center at the Medical University of South Carolina (MUSC). He is an expert in the field of GP96/GRP94 chaperone and played important roles in advancing HSP–based cancer vaccines. He recently uncovered the roles of platelets especially the TGFbeta-GARP axis on the platelets in immune tolerance and cancer immunotherapy, and discovered CNPY2 as a key initiator of the unfolded protein response. His laboratory has been continuously funded by NIH for the last two decades. Dr. Li has served multiple leadership roles in the American Society of Clinical Oncology (ASCO) and the Chinese American Hematologist and Oncologist Network (CAHON). He has been leading the effort to establish the Committee of Overseas Experts (COE) of the Chinese Society of Clinical Oncology (CSCO) and is the elected founding chair of the CSCO COE (2018-2020).